Oncology Institute Net Income
| TOI Stock | USD 2.61 0.16 6.53% |
As of the 6th of February, Oncology Institute holds the Risk Adjusted Performance of (0.09), variance of 34.99, and Coefficient Of Variation of (800.37). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncology Institute, as well as the relationship between them.
Oncology Institute Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.7482 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -58.2 M | -55.3 M | |
| Net Income Applicable To Common Shares | 61.2 K | 64.3 K | |
| Net Loss | -47.7 M | -45.3 M | |
| Net Loss | (0.99) | (0.94) | |
| Net Income Per E B T | 1.15 | 0.66 |
Oncology | Net Income | Build AI portfolio with Oncology Stock |
The Net Income trend for Oncology Institute offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Oncology Institute is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Oncology Institute's Net Income Growth Pattern
Below is the plot of the Net Income of Oncology Institute over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Oncology Institute financial statement analysis. It represents the amount of money remaining after all of Oncology Institute operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Oncology Institute's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (53.01 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Oncology Net Income Regression Statistics
| Arithmetic Mean | (14,988,261) | |
| Coefficient Of Variation | (198.67) | |
| Mean Deviation | 23,677,826 | |
| Median | 3,947,974 | |
| Standard Deviation | 29,777,345 | |
| Sample Variance | 886.7T | |
| Range | 87M | |
| R-Value | (0.77) | |
| Mean Square Error | 380.5T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (4,558,710) | |
| Total Sum of Squares | 14187T |
Oncology Net Income History
Other Fundumenentals of Oncology Institute
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Oncology Institute Net Income component correlations
Oncology Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncology Institute is extremely important. It helps to project a fair market value of Oncology Stock properly, considering its historical fundamentals such as Net Income. Since Oncology Institute's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncology Institute's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncology Institute's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will Oncology introduce new products? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.67) | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets | Return On Equity |
Investors evaluate Oncology Institute using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oncology Institute's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Oncology Institute's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Oncology Institute's market price signifies the transaction level at which participants voluntarily complete trades.
Oncology Institute 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oncology Institute's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oncology Institute.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Oncology Institute on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Oncology Institute or generate 0.0% return on investment in Oncology Institute over 90 days. Oncology Institute is related to or competes with Enhabit, Auna SA, Sonida Senior, Cross Country, Evolus, Treace Medical, and Orthopediatrics Corp. The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States More
Oncology Institute Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oncology Institute's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oncology Institute upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 42.16 | |||
| Value At Risk | (8.31) | |||
| Potential Upside | 6.53 |
Oncology Institute Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncology Institute's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oncology Institute's standard deviation. In reality, there are many statistical measures that can use Oncology Institute historical prices to predict the future Oncology Institute's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.81) | |||
| Total Risk Alpha | (1.03) | |||
| Treynor Ratio | (0.45) |
Oncology Institute February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 4.17 | |||
| Coefficient Of Variation | (800.37) | |||
| Standard Deviation | 5.92 | |||
| Variance | 34.99 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.81) | |||
| Total Risk Alpha | (1.03) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 42.16 | |||
| Value At Risk | (8.31) | |||
| Potential Upside | 6.53 | |||
| Skewness | 1.75 | |||
| Kurtosis | 8.56 |
Oncology Institute Backtested Returns
Oncology Institute maintains Sharpe Ratio (i.e., Efficiency) of -0.0554, which implies the firm had a -0.0554 % return per unit of risk over the last 3 months. Oncology Institute exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oncology Institute's Risk Adjusted Performance of (0.09), coefficient of variation of (800.37), and Variance of 34.99 to confirm the risk estimate we provide. The company holds a Beta of 1.66, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oncology Institute will likely underperform. At this point, Oncology Institute has a negative expected return of -0.33%. Please make sure to check Oncology Institute's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Oncology Institute performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.41 |
Modest reverse predictability
Oncology Institute has modest reverse predictability. Overlapping area represents the amount of predictability between Oncology Institute time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oncology Institute price movement. The serial correlation of -0.41 indicates that just about 41.0% of current Oncology Institute price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.41 | |
| Spearman Rank Test | -0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.24 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Oncology Institute reported net income of (53.01 Million). This is 115.53% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 109.28% higher than that of the company.
Oncology Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncology Institute's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncology Institute could also be used in its relative valuation, which is a method of valuing Oncology Institute by comparing valuation metrics of similar companies.Oncology Institute is currently under evaluation in net income category among its peers.
Oncology Institute Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oncology Institute from analyzing Oncology Institute's financial statements. These drivers represent accounts that assess Oncology Institute's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oncology Institute's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 645.7M | 120.1M | 150.4M | 23.2M | 26.7M | 25.3M | |
| Enterprise Value | 531.6M | 214.3M | 236.6M | 96.7M | 111.2M | 105.6M |
Oncology Institute ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oncology Institute's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oncology Institute's managers, analysts, and investors.Environmental | Governance | Social |
Oncology Institute Institutional Holders
Institutional Holdings refers to the ownership stake in Oncology Institute that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Oncology Institute's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oncology Institute's value.| Shares | Ubs Group Ag | 2025-06-30 | 420.4 K | Northern Trust Corp | 2025-06-30 | 411.4 K | Millennium Management Llc | 2025-06-30 | 405 K | Fourworld Capital Management Llc | 2025-06-30 | 391.6 K | Freegulliver, Llc | 2025-06-30 | 343.8 K | Josh Arnold Investment Consultant, Llc | 2025-06-30 | 291.1 K | Two Sigma Investments Llc | 2025-06-30 | 278.2 K | Manatuck Hill Partners Llc | 2025-06-30 | 249.8 K | Bank Of New York Mellon Corp | 2025-06-30 | 248.6 K | Vanguard Group Inc | 2025-06-30 | 4.3 M | Tiff Advisory Services Inc | 2025-06-30 | 3.6 M |
Oncology Fundamentals
| Return On Equity | -6.52 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 339.55 M | ||||
| Shares Outstanding | 93.5 M | ||||
| Shares Owned By Insiders | 8.88 % | ||||
| Shares Owned By Institutions | 43.33 % | ||||
| Number Of Shares Shorted | 6.95 M | ||||
| Price To Earning | 190.67 X | ||||
| Price To Book | 0.76 X | ||||
| Price To Sales | 0.55 X | ||||
| Revenue | 393.41 M | ||||
| Gross Profit | 63.75 M | ||||
| EBITDA | (53.83 M) | ||||
| Net Income | (53.01 M) | ||||
| Cash And Equivalents | 64.21 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 123.15 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 3.11 X | ||||
| Book Value Per Share | (0.1) X | ||||
| Cash Flow From Operations | (26.54 M) | ||||
| Short Ratio | 2.40 X | ||||
| Earnings Per Share | (0.67) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 825 | ||||
| Beta | 0.16 | ||||
| Market Capitalization | 287.99 M | ||||
| Total Asset | 172.72 M | ||||
| Retained Earnings | (210.81 M) | ||||
| Working Capital | 60.2 M | ||||
| Net Asset | 172.72 M |
About Oncology Institute Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncology Institute's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncology Institute using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncology Institute based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is there potential for Health Care Equipment & Supplies market expansion? Will Oncology introduce new products? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.67) | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets | Return On Equity |
Investors evaluate Oncology Institute using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oncology Institute's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Oncology Institute's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Oncology Institute's market price signifies the transaction level at which participants voluntarily complete trades.